Neuroscience
From the FDA:
FDA NEWS RELEASE
For Immediate Release: Oct. 24, 2011
FDA approves Onfi to treat severe type of seizures
On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United States, it was granted orphan drug designation by the FDA.
“Lennox-Gastaut syndrome is a severe form of epilepsy that causes debilitating seizures,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is a difficult condition to treat, and it will be helpful to have an additional treatment option.”
Read the full release
- Epilepsy: Fda Approves Aptiom (eslicarbazepine Acetate) To Treat Seizures In Adults
...
- Fda: Saphris (asenapine) Approval, Schizophrenia And Bipolar
From the FDA: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat...
- Fda Approves Invega (paliperidone)
An FDA Press Release: FOR IMMEDIATE RELEASE P06-208 December 20, 2006 Media Inquiries: Press Office, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves New Drug for Schizophrenia The Food and Drug Administration (FDA) today approved Invega (paliperidone)...
- Fda: Alzheimer Disease, Aricept (donepezil Hydrochloride)
From the FDA last week: FDA Approves Expanded Use of Treatment for Patients With Severe Alzheimer's Disease FOR IMMEDIATE RELEASE P06-168 October 13, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA...
- Business World: Cyberonics, Neurostimulator (vagus Nerve Stimulator [vns]), And Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.) From the company's press release:FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD) First FDA-Approved...
Neuroscience
News from the FDA: Onfi tablets (clobazam) for Adjunctive Treatment in Lennox-Gastaut Syndrome
From the FDA:
FDA NEWS RELEASE
For Immediate Release: Oct. 24, 2011
FDA approves Onfi to treat severe type of seizures
On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United States, it was granted orphan drug designation by the FDA.
“Lennox-Gastaut syndrome is a severe form of epilepsy that causes debilitating seizures,” said Russell Katz, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is a difficult condition to treat, and it will be helpful to have an additional treatment option.”
Read the full release
- Epilepsy: Fda Approves Aptiom (eslicarbazepine Acetate) To Treat Seizures In Adults
...
- Fda: Saphris (asenapine) Approval, Schizophrenia And Bipolar
From the FDA: FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder The U.S. Food and Drug Administration has approved Saphris tablets (asenapine) to treat adults with schizophrenia, a chronic, severe and disabling brain disorder, and to treat...
- Fda Approves Invega (paliperidone)
An FDA Press Release: FOR IMMEDIATE RELEASE P06-208 December 20, 2006 Media Inquiries: Press Office, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Approves New Drug for Schizophrenia The Food and Drug Administration (FDA) today approved Invega (paliperidone)...
- Fda: Alzheimer Disease, Aricept (donepezil Hydrochloride)
From the FDA last week: FDA Approves Expanded Use of Treatment for Patients With Severe Alzheimer's Disease FOR IMMEDIATE RELEASE P06-168 October 13, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA...
- Business World: Cyberonics, Neurostimulator (vagus Nerve Stimulator [vns]), And Depression
News about this controversial issue (See the list at the bottom of this posting for earlier BrainBlog posts.) From the company's press release:FDA APPROVES CYBERONICS’ VNS THERAPY™ SYSTEM FOR TREATMENT-RESISTANT DEPRESSION (TRD) First FDA-Approved...